PDCD1 and thyroiditis: In urothelial carcinoma, the frequency of thyroiditis was similar between anti-PD-1 and -PD-L1 therapies (10–15%), although hypothyroidism appeared somewhat more frequent with PD-L1 blockade (up to 13%).